PL2519515T3 - Pochodne pirazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych - Google Patents

Pochodne pirazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych

Info

Publication number
PL2519515T3
PL2519515T3 PL10796064T PL10796064T PL2519515T3 PL 2519515 T3 PL2519515 T3 PL 2519515T3 PL 10796064 T PL10796064 T PL 10796064T PL 10796064 T PL10796064 T PL 10796064T PL 2519515 T3 PL2519515 T3 PL 2519515T3
Authority
PL
Poland
Prior art keywords
treatment
neurological disorders
pyrazine derivatives
pyrazine
derivatives
Prior art date
Application number
PL10796064T
Other languages
English (en)
Inventor
Marina Tintelnot-Blomley
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2519515(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2519515T3 publication Critical patent/PL2519515T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10796064T 2009-12-31 2010-12-22 Pochodne pirazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych PL2519515T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29172409P 2009-12-31 2009-12-31
PCT/EP2010/070502 WO2011080176A1 (en) 2009-12-31 2010-12-22 Pyrazine derivatives and their use in the treatment of neurological disorders
EP20100796064 EP2519515B1 (en) 2009-12-31 2010-12-22 Pyrazine derivatives and their use in the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
PL2519515T3 true PL2519515T3 (pl) 2014-04-30

Family

ID=43598456

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10796064T PL2519515T3 (pl) 2009-12-31 2010-12-22 Pochodne pirazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych

Country Status (27)

Country Link
US (2) US20120277244A1 (pl)
EP (1) EP2519515B1 (pl)
JP (1) JP5600754B2 (pl)
KR (1) KR101419157B1 (pl)
CN (1) CN102712621B (pl)
AU (1) AU2010338365B2 (pl)
BR (1) BR112012015916A2 (pl)
CA (1) CA2785341A1 (pl)
CL (1) CL2012001762A1 (pl)
CR (1) CR20120332A (pl)
CU (1) CU20120099A7 (pl)
EA (1) EA201200952A1 (pl)
EC (1) ECSP12012065A (pl)
ES (1) ES2445536T3 (pl)
GT (1) GT201200219A (pl)
HK (1) HK1172023A1 (pl)
HN (1) HN2012001413A (pl)
IL (1) IL220268A0 (pl)
MX (1) MX2012007754A (pl)
NZ (1) NZ600136A (pl)
PE (1) PE20121640A1 (pl)
PL (1) PL2519515T3 (pl)
PT (1) PT2519515E (pl)
SG (1) SG181431A1 (pl)
TN (1) TN2012000249A1 (pl)
WO (1) WO2011080176A1 (pl)
ZA (1) ZA201203614B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2597087B1 (en) 2005-10-25 2016-03-30 Shionogi&Co., Ltd. Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
CA2727859C (en) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
ES2590038T5 (es) 2009-12-11 2021-10-19 Shionogi & Co Derivado de oxazina
US20130109683A1 (en) 2010-06-09 2013-05-02 Janssen Pharmaceutica Nv 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
JP2013531644A (ja) * 2010-06-09 2013-08-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ βセクレターゼ（ＢＡＣＥ）の阻害剤として有用な５−アミノ−３，６−ジヒドロ−１Ｈ−ピラジン−２−オン誘導体
SG186408A1 (en) * 2010-06-28 2013-01-30 Janssen Pharmaceutica Nv 3-amino-5, 6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia
AU2011321427A1 (en) 2010-10-29 2013-05-02 Shionogi & Co., Ltd. Naphthyridine derivative
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
JP5834091B2 (ja) 2010-12-22 2015-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ベータ−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な５，６−ジヒドロ−イミダゾ［１，２−ａ］ピラジン−８−イルアミン誘導体
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
MY162413A (en) 2011-01-13 2017-06-15 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2013008192A (es) * 2011-01-13 2013-12-16 Novartis Ag Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MY161407A (en) 2011-03-01 2017-04-14 Janssen Pharmaceutica Nv 6,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
KR102012675B1 (ko) 2011-03-09 2019-08-21 얀센 파마슈티카 엔.브이. 베타-세크레타제(BACE)의 억제제로서 유용한 3,4-디하이드로-피롤로[1,2-a]피라진-1-일아민 유도체
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9499502B2 (en) 2011-04-13 2016-11-22 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
JP2014524472A (ja) 2011-08-22 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害剤としての２−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
EP2934539B1 (en) 2012-12-20 2019-03-27 Merck Sharp & Dohme Corp. C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors
BR112015030678A8 (pt) 2013-06-12 2020-01-07 Janssen Pharmaceutica Nv derivados 4-amino-6-fenil-5,6-di-hidroimidazo [1,5-a] pirazina como inibidores de beta-secretase (bace), composição farmacêutica, processo para preparação da mesma, e usos na fabricação de medicamentos
WO2014198854A1 (en) 2013-06-12 2014-12-18 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
MX368326B (es) 2013-06-12 2019-09-27 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace).
ES2768823T3 (es) 2014-12-18 2020-06-23 Janssen Pharmaceutica Nv Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa
CN107011134B (zh) * 2017-04-28 2021-02-05 浙江中欣氟材股份有限公司 一种2-氟-5-溴苯乙酮的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (pl) 1968-08-31 1970-03-03
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
EP1363702A4 (en) * 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
NZ548128A (en) 2003-12-29 2010-05-28 Banyu Pharma Co Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
US20050215884A1 (en) * 2004-02-27 2005-09-29 Greicius Michael D Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI
EP2597087B1 (en) * 2005-10-25 2016-03-30 Shionogi&Co., Ltd. Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
KR101331768B1 (ko) * 2005-11-08 2013-11-22 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
AU2009205072C1 (en) 2008-01-18 2016-10-13 Eisai R & D Management Co., Ltd. Condensed aminodihydrothiazine derivative
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
UY32799A (es) * 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
JP2013531644A (ja) * 2010-06-09 2013-08-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ βセクレターゼ（ＢＡＣＥ）の阻害剤として有用な５−アミノ−３，６−ジヒドロ−１Ｈ−ピラジン−２−オン誘導体
SG186408A1 (en) * 2010-06-28 2013-01-30 Janssen Pharmaceutica Nv 3-amino-5, 6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia

Also Published As

Publication number Publication date
US20120277244A1 (en) 2012-11-01
HK1172023A1 (en) 2013-04-12
CN102712621A (zh) 2012-10-03
GT201200219A (es) 2013-10-10
AU2010338365B2 (en) 2014-01-30
TN2012000249A1 (en) 2013-12-12
ES2445536T3 (es) 2014-03-03
PE20121640A1 (es) 2012-12-17
PT2519515E (pt) 2014-02-17
US20150322038A1 (en) 2015-11-12
NZ600136A (en) 2013-09-27
CR20120332A (es) 2012-07-12
JP2013516395A (ja) 2013-05-13
CU20120099A7 (es) 2012-07-31
JP5600754B2 (ja) 2014-10-01
EP2519515A1 (en) 2012-11-07
ZA201203614B (en) 2013-01-30
SG181431A1 (en) 2012-07-30
KR20120102795A (ko) 2012-09-18
ECSP12012065A (es) 2012-08-31
AU2010338365A1 (en) 2012-06-07
CL2012001762A1 (es) 2012-12-21
CN102712621B (zh) 2015-03-11
CA2785341A1 (en) 2011-07-07
MX2012007754A (es) 2012-08-01
EP2519515B1 (en) 2013-11-06
IL220268A0 (en) 2012-07-31
BR112012015916A2 (pt) 2017-04-25
EA201200952A1 (ru) 2013-02-28
KR101419157B1 (ko) 2014-07-11
WO2011080176A1 (en) 2011-07-07
HN2012001413A (es) 2015-03-23

Similar Documents

Publication Publication Date Title
HK1172023A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
HK1168091A1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
AP3807A (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
ZA201109384B (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
ZA201100482B (en) Pyrazolopyrimidines and their use for the treatment of cns disorders
IL205108A0 (en) Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
HK1170485A1 (zh) -噻唑烷- -酮衍生物及其在癌症治療中的用途
EP2268140A4 (en) NOVEL COMPOUNDS FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EP2278972A4 (en) TREATMENT FOR NEUROLOGICAL AND MENTAL DISORDERS
EP2393945A4 (en) DOUBLE TARGETING OF MIR-208 AND MIR-499 IN THE TREATMENT OF CARDIAC DISORDERS
GB0904044D0 (en) The treatment of inflammatory disorders and pain
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
HK1145282A1 (en) Treatment of sleep disorders
GB0814043D0 (en) The treatment of skin disorders
TH134234B (th) สารอนุพันธ์ไพราซีน (Pyrazine derivatives) และ การใช้ของสารนั้นในการบำบัด ของความผิกปกติทางประสาท
GB0817330D0 (en) The treatment of inflammatory disorders and pain
GB0803397D0 (en) The treatment of inflammatory disorders and pain
GB0722524D0 (en) The treatment of inflammatory disorders and pain
GB0718279D0 (en) The treatment of inflammatory disorders and pain
GB0711769D0 (en) The treatment of inflammatory disorders and pain
GB0703494D0 (en) The treatment of inflammatory disorders and pain
AU2010901520A0 (en) Substituted thienobenzodiazepines and their use in the treatment of CNS disorders